• Submit to Cancers Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• For Librarians
• About
• Open Access Policy

• Abstract
• Full-Text HTML
• Full-Text PDF [371 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• PubMed/Medline
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Grassadonia, A
• Cioffi, P
• Simiele, F
• Iezzi, L
• Zilli, M
• Natoli, C
• [+] on Google Scholar
• Grassadonia, A
• Cioffi, P
• Simiele, F
• Iezzi, L
• Zilli, M
• Natoli, C
• [+] on PubMed
• Grassadonia, A
• Cioffi, P
• Simiele, F
• Iezzi, L
• Zilli, M
• Natoli, C

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter
• More services

Open AccessThis article is

• freely available
• re-usable

Cancers 2013, 5(3), 919-942; doi:10.3390/cancers5030919

Review

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies

Antonino Grassadonia ¹, Pasquale Cioffi ², Felice Simiele ², Laura Iezzi ³, Marinella Zilli ³ and Clara Natoli ^1,*

¹ Department of Experimental and Clinical Sciences, University 'G. d'Annunzio', I-66013 Chieti, Italy ² Hospital Pharmacy, "SS. Annunziata" Hospital, I-66013 Chieti, Italy ³ Oncology Department, "SS. Annunziata" Hospital, I-66013 Chieti, Italy

* Author to whom correspondence should be addressed.

Received: 22 April 2013; in revised form: 3 July 2013 / Accepted: 12 July 2013 / Published: 25 July 2013

(This article belongs to the Special Issue Cancer Epigenetics)

Download PDF Full-Text [371 KB, uploaded 25 July 2013 09:37 CEST]

Abstract: Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a variety of cytotoxic and molecular targeted agents in many different solid tumors, including breast, prostate, pancreatic, lung and ovarian cancer. Hb-HDACIs have a quite good toxicity profile and are now being tested in phase I and II clinical trials in solid tumors with promising results in selected neoplasms, such as hepatocarcinoma. This review will focus on their clinical activity and safety in patients with advanced solid neoplasms.

Keywords: hydroxamate-based histone deacetylase inhibitors; histone deacetylase inhibitors; vorinostat; belinostat; panobinostat; pracinostat; abexinostat; resminostat

Article Statistics

Citations to this Article

Cite This Article